Renaissance Capital logo

NGM News

NASHville: 89bio is the latest biotech IPO targeting liver disease NASH

NGM Biopharmaceuticals logo

Backed by OrbiMed and Longitude, Phase 1 biotech 89bio (ETNB) is expected to raise $70 million tonight in the fifth NASH-focused biotech IPO of 2019; insiders have indicated on $40 million (57% of the deal). Another NASH...read more

US IPO Weekly Recap: Growth IPOs take the lead in a 5-IPO week

TW

Five IPOs raised $1.4 billion in the IPO market this past week. Silk Road Medical (SILK) took the top spot, spiking 81% on its first day. The company priced well above its range to raise $120 million, 60% more than anticipated. It follows in...read more

NASH biotech NGM Biopharmaceuticals prices IPO at $16, the high end of the range

NGM Biopharmaceuticals logo

NGM Biopharmaceuticals, a Phase 2 biotech developing therapies for NASH and type 2 diabetes, raised $107 million by offering 6.7 million shares at $16, the high end of the range of $14 to $16. NGM Biopharmaceuticals plans to list on the Nasdaq under the symbol...read more

US IPO Week Ahead: Tradeweb is the hot trade in a 4-IPO week

TW

Four IPOs are scheduled to raise nearly $1.0 billion in the week ahead. Electronic trading platform Tradeweb Markets (TW) is the week's largest deal, accounting for about 70% of the week's proceeds. The other three offer growth potential...read more